{"id":1661,"date":"2017-01-18T16:52:23","date_gmt":"2017-01-18T21:52:23","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=1661"},"modified":"2017-01-18T16:52:23","modified_gmt":"2017-01-18T21:52:23","slug":"secondaries-announced-01-18-2017","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-01-18-2017\/","title":{"rendered":"Secondaries announced 01.18.2017"},"content":{"rendered":"<p>IPOBoutique.Com rates secondary offerings to hit the tape with a \u2018BUY\u2019, \u2018NEUTRAL\u2019 or \u2018AVOID\u2019 rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary\u2019s he\u2019s issued with a \u2018BUY\u2019 rating. <\/p>\n<p>Company:\tHeron Therapeutics<br \/>\nSymbol:\tHRTX<br \/>\nPrice:\t\tLast trade $12.80<br \/>\nDescription:\tRe-offer range $12.00-$12.30<br \/>\nTrade Date:\t1\/19<br \/>\nShares:\t11.7 million<br \/>\nUnderwriter(s)BofA Merrill Lynch, Cowen, Leerink<br \/>\n<a href=\" https:\/\/www.ipoboutique.com\/Subscribe.html\">Rating=Subscription Needed<\/a><\/p>\n<p>Company:\tApollo Global Management-BLOCK<br \/>\nSymbol:\tAPO<br \/>\nPrice:\t\tLast trade $21.20<br \/>\nDescription:\tRe-offer $20.70-$20.90<br \/>\nTrade Date:\t1\/19<br \/>\nShares:\t5 million<br \/>\nUnderwriter(s)Morgan Stanley<br \/>\n<a href=\" https:\/\/www.ipoboutique.com\/Subscribe.html\">Rating=Subscription Needed<\/a><\/p>\n<p>Company:\tViper Energy Partners LP<br \/>\nSymbol:\tVNOM<br \/>\nPrice:\t\tLast trade $16.72<br \/>\nDescription:\tRe-offer $15.20-$15.70<br \/>\nTrade Date:\t1\/19<br \/>\nShares:\t7 million<br \/>\nUnderwriter(s)Credit Suisse, Citigroup, UBS<br \/>\n<a href=\" https:\/\/www.ipoboutique.com\/Subscribe.html\">Rating=Subscription Needed<\/a><\/p>\n<p>Company:\tZynerba Pharmaceuticals, Inc.<br \/>\nSymbol:\tZYNE<br \/>\nPrice:\t\tLast trade $22.46<br \/>\nDescription:\tRe-offer $18.00-$19.00<br \/>\nTrade Date:\t1\/19<br \/>\nShares:\t1.8 million<br \/>\nUnderwriter(s)Jefferies, Piper Jaffray<br \/>\n<a href=\" https:\/\/www.ipoboutique.com\/Subscribe.html\">Rating=Subscription Needed<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IPOBoutique.Com rates secondary offerings to hit the tape with a \u2018BUY\u2019, \u2018NEUTRAL\u2019 or \u2018AVOID\u2019 rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary\u2019s he\u2019s issued with a \u2018BUY\u2019 rating. Company: Heron Therapeutics Symbol: HRTX Price: Last trade $12.80 Description: Re-offer range $12.00-$12.30 Trade Date: 1\/19 Shares: 11.7 million Underwriter(s)BofA Merrill Lynch,[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[1028,461,863,576],"class_list":["post-1661","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings","tag-apo","tag-hrtx","tag-vnom","tag-zyne"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/1661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=1661"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/1661\/revisions"}],"predecessor-version":[{"id":1662,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/1661\/revisions\/1662"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=1661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=1661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=1661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}